改善急性呼吸窘迫综合征临床试验设计的机会
急性呼吸窘迫综合征(ARDS)是常见危重症,致残率和死亡率高,目前尚无已验证的药物治疗。当前ARDS定义基于共同临床特征,但未捕捉临床危险因素、影像学特征、生理学、发病时间和轨迹以及生物学上的异质性。ARDS临床试验界越来越关注设计能减少试验人群异质性的临床试验,但这必须与制定包容性全球ARDS定义的工作相平衡,后者对试验设计有重要影响。本文推荐两种主要策略:开发新方法以针对临床试验人群中的可治疗特征,以及提高ARDS试验的代表性并纳入全球人群;这两种策略互补,并讨论了拟议扩展ARDS定义可能如何影响临床试验的未来。
要点
- ARDS是常见危重症,致残率和死亡率高,目前尚无已验证的药物治疗。
- 当前ARDS定义基于共同临床特征,但未捕捉临床危险因素、影像学特征、生理学、发病时间和轨迹以及生物学上的异质性。
- ARDS临床试验界越来越关注设计能减少试验人群异质性的临床试验,但需与制定包容性全球ARDS定义的工作相平衡。
- 本文推荐两种主要策略:开发新方法以针对临床试验人群中的可治疗特征,以及提高ARDS试验的代表性并纳入全球人群;这两种策略互补。
- 本文还讨论了拟议扩展ARDS定义可能如何影响临床试验的未来。
证据类型、等级与局限
- 证据类型:个人观点(Personal View)。
- 局限:原文未报告局限性。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「适用人群与场景」「诊断标准与关键阈值」「处置流程与药物剂量」「红旗征与不能漏的情况」「研究设计与关键结果」「对床旁实践的改变」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
The acute respiratory distress syndrome (ARDS) is a common critical illness syndrome with high morbidity and mortality. There are no proven pharmacological therapies for ARDS. The current definition of ARDS is based on shared clinical characteristics but does not capture the heterogeneity in clinical risk factors, imaging characteristics, physiology, timing of onset and trajectory, and biology of the syndrome. There is increasing interest within the ARDS clinical trialist community to design clinical trials that reduce heterogeneity in the trial population. This effort must be balanced with ongoing work to craft an inclusive, global definition of ARDS, with important implications for trial design. Ultimately, the two aims-to design trials that are applicable to the diverse global ARDS population while also advancing opportunities to identify targetable traits-should coexist. In this Personal View, we recommend two primary strategies to improve future ARDS trials: the development of new methods to target treatable traits in clinical trial populations, and improvements in the representativeness of ARDS trials, with the inclusion of global populations. We emphasise that these two strategies are complementary. We also discuss how a proposed expansion of the definition of ARDS could affect the future of clinical trials.
参考来源
- Wick KD, Aggarwal NR, Curley MAQ, et al. Opportunities for improved clinical trial designs in acute respiratory distress syndrome. Lancet Respir Med. 2022. PMID: 36057279. doi:10.1016/S2213-2600(22)00294-6
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。